Significant Validation of AI-Immunology™ Platform
The AI-Immunology™ platform developed by Evaxion Biotech A/S has demonstrated strong efficacy across multiple clinical trials. Strong data from these trials highlight its capability to accurately identify clinically relevant vaccine targets, reinforcing the platform's role in modern immunotherapy.
Overview of Clinical Trial Results
Recent findings indicate that the AI-Immunology™ platform not only predicts vaccine targets but also optimizes them based on real-world evidence. Notably, the strongest outcomes stemmed from the top-ranked vaccine targets identified through the platform, further linking AI-driven design to actual clinical effectiveness.
Personalized Cancer Vaccines Developed
Evaxion has successfully utilized its AI-Immunology™ technology to create personalized cancer vaccine candidates. Noteworthy candidates include EVX-01 and EVX-02, both of which have recently completed clinical phase 1 testing. Currently, EVX-01 is progressing through phase 2 trials, while EVX-03 stands as an IND-ready candidate, showcasing a significant leap forward in individualized cancer treatment.
Role of Neoantigens in Cancer Treatment
Central to the platform's design is the identification of neoantigens—novel protein fragments recognized by the immune system as threats. The prediction scores generated by AI-Immunology™ reveal a strong correlation between these scores and immunological responses observed in patients. In all clinical trials conducted, the data indicates substantial immune responses linked to higher prediction scores, emphasizing the platform's predictive accuracy.
Progression Free Survival Insights
In one of the trials, researchers assessed the impact of AI-Immunology™ prediction scores on Progression Free Survival (PFS). The results demonstrated a statistically significant correlation, validating the platform's ability to discover vaccine targets that not only provoke immune reactions but also contribute to meaningful clinical benefits for patients.
CEO Insights on Platform's Future
Christian Kanstrup, CEO of Evaxion, expressed pride in the clinical data collected thus far, highlighting the unique predictive capabilities of the AI-Immunology™ platform. The results serve as robust guidance for future development efforts concerning personalized cancer vaccines. Continuous data generation plays a pivotal role in refining the platform, enhancing its commercial potential.
Understanding AI-Immunology™
AI-Immunology™ is engineered to be both scalable and adaptable, placing it at the forefront of vaccine discovery for both infectious diseases and cancers. By leveraging proprietary AI models, including PIONEER™, EDEN™, RAVEN™, and ObsERV™, the platform adeptly models the complexities of the human immune system. This innovative approach enables rapid identification and design of vaccine candidates tailored to combat rapidly evolving diseases.
Contact Information for Inquiries
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
Email: mak@evaxion-biotech.com
Frequently Asked Questions
What is the AI-Immunology™ platform?
The AI-Immunology™ platform is a cutting-edge technology designed to improve vaccine discovery and development using artificial intelligence.
How many clinical trials has Evaxion conducted?
Evaxion has conducted three clinical trials to validate its AI-Immunology™ platform's predictions for vaccine targets.
What is the significance of neoantigens?
Neoantigens are unique cancer targets that the immune system can recognize, making them crucial for personalized cancer vaccines.
What is Evaxion's goal with AI-Immunology™?
Evaxion’s goal is to develop personalized vaccines using AI technology to enhance treatment outcomes in cancer and infectious diseases.
Who should I contact for more information about Evaxion?
You can reach out to Mads Kronborg at Evaxion Biotech for inquiries regarding the company and its projects.
